Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma-Reference-Cited by-同舟云学术

Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma

Published:2021-06-17 Issue:9 Volume:20 Page:1584-1591
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Karajannis Matthias A.^ORCID,Mauguen Audrey^ORCID,Maloku Ekrem,Xu Qingwen,Dunbar Erin M.,Plotkin Scott R.^ORCID,Yaffee Anna,Wang Shiyang,Roland J. Thomas,Sen Chandranath,Placantonakis Dimitris G.^ORCID,Golfinos John G.^ORCID,Allen Jeffrey C.,Vitanza Nicholas A.^ORCID,Chiriboga Luis A.^ORCID,Schneider Robert J.^ORCID,Deng Jingjing,Neubert Thomas A.^ORCID,Goldberg Judith D.^ORCID,Zagzag David,Giancotti Filippo G.,Blakeley Jaishri O.^ORCID

Funder

NIHNCINCI

Novartis, Inc

NIHORIPORIP

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumors of the nervous system and hearing loss: Beyond vestibular schwannomas;Hearing Research;2024-06

2. Updates on Revised Diagnostic Criteria and Targeted Therapies for Neurofibromatosis;Advances in Oncology;2024-05

3. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma;Journal of Neuro-Oncology;2024-02-19

4. Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningioma;Cancer Cell International;2024-01-18

5. Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis;Current Oncology Reports;2023-10-31